The Financial Post reports in its Thursday, May 14, edition that Dr. Reddy's Laboratories plans to launch its version of generic Ozempic this month in Canada after a key patent expiry paves the way for cheaper GLP-1 drugs. A Bloomberg dispatch to the Post reports that chief executive officer Erez Israeli says Dr. Reddy's generic will be offered at a "very healthy price." Pricing details were not disclosed. Health Canada approved its application last month, after issuing a negative review last year. Exclusivity on semaglutide -- the key ingredient in Novo Nordisk's Ozempic and Wegovy -- expired in Canada on Jan. 4. The release would make Canada the second country with generic Ozempic after India, and lay the groundwork for proliferation of cheaper, non-branded versions of the diabetes and weight-loss drugs globally. Health Canada also approved Apotex's application on May 1, and is reviewing seven other submissions by other firms. It expects to make decisions in the coming weeks and months. Apotex plans to have its generic semaglutide available in Canada by the end of May. Mr. Israeli says with limited competition "the price will likely be higher initially and then drop as more companies start selling."